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The RNA-mediated disease model for myotonic
dystrophy (DM) proposes that microsatellite C(C)TG
expansions express toxic RNAs that disrupt splicing
regulation by altering MBNL1 and CELF1 activities.
While this model explains DM manifestations in
muscle, less is known about the effects of C(C)UG
expression on the brain. Here, we report that
Mbnl2 knockout mice develop several DM-associ-
ated central nervous system (CNS) features
including abnormal REM sleep propensity and defi-
cits in spatial memory. Mbnl2 is prominently ex-
pressed in the hippocampus and Mbnl2 knockouts
show a decrease in NMDA receptor (NMDAR)
synaptic transmission and impaired hippocampal
synaptic plasticity. While Mbnl2 loss did not sig-
nificantly alter target transcript levels in the hippo-
campus, misregulated splicing of hundreds of exons
was detected using splicing microarrays, RNA-seq,
and HITS-CLIP. Importantly, the majority of the
Mbnl2-regulated exons examined were similarly
misregulated in DM. We propose that major patho-
logical features of the DM brain result from disrup-
tion of the MBNL2-mediated developmental splicing
program.INTRODUCTION
During mammalian development, alternative splicing of pre-
mRNAs plays a critical role in the extensive remodeling of tissues
throughout both embryonic and postnatal phases (Chen and
Manley, 2009; Kalsotra and Cooper, 2011). The spatial and
temporal expression patterns of specific protein isoforms are
exquisitely controlled during each developmental window such
that the unique physiological requirements of each cell type
are adequately met. While >90% of human multiexon genes
produce alternatively spliced transcripts, the complex network
of dynamic interactions between multiple cell types that charac-
terizes the central nervous system (CNS) suggests that alterna-
tive splicing regulation is particularly critical for the developing
brain (Li et al., 2007; Licatalosi and Darnell, 2010; Wang et al.,
2008).
The importance of alternative splicing during developmental
transitions has been highlighted by studies on the autosomal
dominant disease myotonic dystrophy (DM) (Cooper et al.,
2009; Poulos et al., 2011). CNS function is compromised in DM
with hypersomnia, cognitive and behavioral abnormalities,
progressive memory problems, cerebral atrophy, and, in the
congenital form of the disease, mental retardation (Meola and
Sansone, 2007; Weber et al., 2010). DM is caused bymicrosatel-
lite CTG expansions in the DMPK gene (DM type 1 [DM1]) or
CNBP CCTG expansions (DM type 2 [DM2]). Transcription of
these repeats generates C(C)UG expansion [C(C)UGexp] RNAs
that disrupt alternative splicing, resulting in the persistence ofNeuron 75, 437–450, August 9, 2012 ª2012 Elsevier Inc. 437
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Developmental Control of RNA Splicing in the Brainfetal splicing patterns in adult tissues. A current disease model
suggests that splicing disruption occurs because the muscle-
blind-like protein 1 (MBNL1), which normally promotes adult
splicing patterns, is sequestered by C(C)UGexp RNAs (Cooper
et al., 2009; Du et al., 2010; Poulos et al., 2011). Additionally,
expression of C(C)UGexp RNAs is reported to increase levels
of CELF1, a splicing factor that promotes fetal splicing
(Kuyumcu-Martinez et al., 2007). Thus, the developmental regu-
lation of some DM-targeted exons may be achieved by modu-
lating the levels of two antagonistic splicing factors, MBNL1
and CELF1. Although this MBNL loss-of-function model for
DM1 and DM2 is supported by the splicing patterns observed
in the skeletal and heart muscles of mouse Mbnl1 knockouts
and Celf1 overexpression transgenics (Du et al., 2010; Kanadia
et al., 2003; Koshelev et al., 2010; Ward et al., 2010), it is not
clear whether alternative splicing in the brain is similarly dys-
regulated. Moreover, the view that DM is solely a spliceopathy
has been recently challenged (Sicot et al., 2011). The expression
of mutant DMPK and CNBP microsatellites also results in alter-
ations in mRNA localization, microRNA, and mRNA turnover
pathways and induces repeat-associated non-ATG-initiated
(RAN) translation (Zu et al., 2011). These additional pathogenic
mechanisms highlight the importance of discriminating direct
from indirect actions of DM mutations to link specific disease
manifestations to distinct pathways.
Since Mbnl1 knockout (Mbnl1DE3/DE3) mice show modest
effects on alternative splicing regulation in the brain (Suenaga
et al., 2012), we have now addressed the possibility that the
other major MBNL protein expressed in adult tissues, MBNL2,
is the principal factor dysregulated in the DM CNS. Here, we
report the generation of Mbnl2 knockout mice, which exhibit
several phenotypes consistent with features of DM neurologic
disease. Loss of Mbnl2 leads to widespread changes in post-
natal splicing patterns in the brain, many of which are similarly
dysregulated in the human DM1 brain, but not in skeletal muscle.
Direct Mbnl2 RNA targets are identified by high throughput
sequencing-crosslinking immunoprecipitation (HITS-CLIP) and
the generation of an Mbnl2 splicing map. Mbnl2 knockouts
should provide novel insights into the developmental regulation
of splicing in the CNS and identify the molecular events that
impact the brain in myotonic dystrophy.
RESULTS
Mbnl2 Knockout Mice Fail to Model DM-Associated
Muscle Deficits
Previous gene trap studies have reported contradictory results
on the effects of Mbnl2 allele disruption on DM-relevant muscle
pathology and alternative splicing (see Figure S1A available
online). Insertion of an EN2-bgeo gene trap into Mbnl2 intron
4 (Mbnl2GT4) resulted in a decrease in Mbnl2 mRNA in
Mbnl2GT4/GT4 homozygotes but no changes in muscle structure
and function or in the splicing of Mbnl1 RNA targets (Lin et al.,
2006). In contrast, Mbnl2GT2/GT2 mice, in which the same gene
trap had inserted into Mbnl2 intron 2, were reported to develop
myotonia, Clcn1 missplicing, and skeletal muscle defects remi-
niscent of DM (Hao et al., 2008). To address this inconsistency,
we generated Mbnl2 knockout mice (Mbnl2DE2/DE2) using438 Neuron 75, 437–450, August 9, 2012 ª2012 Elsevier Inc.a homologous recombination strategy (Figure S1B). Similar to
Mbnl1 exon 3, Mbnl2 exon 2 encodes the initiation codon for
the full-length Mbnl2 protein (Figure S1C) (Kanadia et al.,
2003). Mbnl2 constitutive knockout lines were generated by
mating chimeric males to a CMV-cre transgenic line (Figure 1A).
Genomic DNA blot analysis confirmed the presence of the dis-
rupted allele in heterozygous and homozygous knockout mice
(Figure S1D). Ablation of full-length Mbnl2 mRNA expression
in the homozygous knockouts was confirmed by RT-PCR (Fig-
ure 1B). While a potential alternative initiation codon exists in
exon 3 (Figure S1C), immunoblot analysis using a monoclonal
antibody (mAb) that recognizes all annotated Mbnl2 isoforms
demonstrated a complete absence of Mbnl2 protein in all
Mbnl2DE2/DE2 tissues examined (Figure 1C). Therefore,
Mbnl2DE2/DE2 lines are functional nulls and will be subsequently
referred to as Mbnl2 knockouts.
Although Mbnl1 protein is expressed at similar levels in adult
skeletal and heart muscle (Figure 1C) and throughout postnatal
development (Ladd et al., 2005), Mbnl2 protein expression in
adult muscle is low compared to other tissues (Figure 1C). This
result is in agreement with prior studies showing that Mbnl2
protein expression is downregulated during myogenic differenti-
ation of C2C12 myoblasts (Bland et al., 2010; Holt et al., 2009).
Mbnl2 knockout adults were small at weaning (Figure 1A, post-
natal day [P] 21) but were normal in weight by P29 (Figure S2A).
Interestingly, DMSXL homozygousmice, which express a human
DMPK transgene with a CTG1200-1700 expansion, are also small
(Gomes-Pereira et al., 2007). Mbnl2 knockouts did not develop
overt skeletal muscle pathology or motor deficits, as assayed
by rotarod analysis, prior to 6 months of age (Figure S2B).
Although a few centralized nuclei were detectable inmuscle cells
of 3- to 5-month-old Mbnl2 knockout mice (Figure S2C),
myotonia was absent and the expression levels and spatial
distribution of the muscle chloride channel Clcn1 was normal
(Figure S2D). Moreover, exons controlled by Mbnl1 in skeletal
muscle and heart showed normal splicing patterns in Mbnl2
knockout adult mice (Figures 1D and 1E). We conclude that if
Mbnl2 functions as a splicing factor in skeletal muscle during
the neonate to adult transition, its targets include few, if any, of
the events known to be perturbed in DM muscle (Du et al.,
2010) and that loss of Mbnl2 alone does not significantly
contribute to DM-like skeletal muscle pathology. Since our
studies were performed onMbnl2 knockouts less than 7 months
of age, we cannot exclude the possibility that loss of Mbnl2
expression contributes to pathology in aging skeletal muscle.
DM Disease-Relevant Phenotypes in Mbnl2
Knockout Mice
Hypersomnia, or excessive daytime sleepiness (EDS), and asso-
ciated perturbations in rapid eye movement (REM) sleep
patterns are among the most characteristic nonmuscle features
of DM (Ciafaloni et al., 2008; Yu et al., 2011). Because Mbnl2
protein was readily detected in multiple regions of the brain (Fig-
ure 1C), we performed sleep electroencephalography/electro-
myography (EEG/EMG) evaluations on Mbnl2 knockout mice;
only males were analyzed since estrous cycles affect sleep
patterns. Mbnl2 knockouts had normal amounts, and natural
diurnal distributions, of wakefulness and non-REM (NREM) sleep
Figure 1. Mbnl2 Knockout Mice Fail to Model DM-Associated Muscle Deficits
(A) Mbnl2DE2/DE2 knockout mice are small at weaning compared to wild-type sibs.
(B) Mbnl2 RNAs containing exon 2 are absent in Mbnl2 knockouts. RT-PCR analysis of hippocampus RNA from Mbnl2+/+, Mbnl2+/DE2, and Mbnl2DE2/DE2 mice
using primers in Mbnl2 exons 1 and 3 is shown. Peptidylprolyl isomerase A (Ppia) was included as a loading control.
(C) Immunoblot showing that Mbnl2 protein, present inMbnl2+/+ mice (WT), is absent inMbnl2 knockouts (KO). Mbnl2 protein was detectable in WT quadriceps
using longer film exposures.Mbnl1, which is abundantly expressed in lung and upregulated inMbnl2 knockout brain, andGapdhwere used as familymember and
loading controls, respectively.
(D) Mbnl1 RNA targets are not misspliced in eitherMbnl2 knockout skeletal (quadriceps) or heart muscles. Splicing patterns were determined using RT-PCR and
Mbnl1+/+ (Mbnl1 WT), Mbnl1DE3/DE3 (Mbnl1 KO), Mbnl2+/+ (Mbnl2 WT), and Mbnl2DE2/DE2 (Mbnl2 KO) RNAs.
(E) Quantification of exon inclusion for alternative splicing of Clcn1, Serca1, Tnnt2, and Sorbs1 (D) RNAs. Data are SEM (n = 3) and only the differences between
Mbnl1+/+ and Mbnl1DE3/DE3 were significant (*p < 0.05).
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(frequent and shorter wake episodes) was also observed in the
knockout mice (Figure 2B). However, the most profound sleep
phenotypes were an increase in REM sleep amounts, associated
with increased numbers of REM sleep episodes (Figures 2A and
2B) and increased EEG theta power (data not shown). This
change was most notable during the dark period when mice
are normally awake. Interestingly, a larger portion of these dark
period REMsleep episodes inMbnl2 knockouts exhibited a short
latency (<100 s) from the preceding wake episodes (Figure 2C).
The mean REM sleep latency of all observed episodes for the
knockouts (115.8 ± 5.4 s) was significantly shorter than that of
wild-type mice (132.3 ± 8.7 s). No direct transition from wake
to REM sleep, an EEG/EMG phenotype equivalent to behavioral
cataplexy (Fujiki et al., 2009), was seen in either wild-type or
knockout mice. A change in REM sleep in Mbnl2 knockouts
was also observed during rebound sleep after a 6 hr sleep depri-
vation period initiated at zeitgeber time (ZT) 0, in which a more
profound REM sleep rebound was observed in knockout,
compared to wild-type, mice (Figure 2D). These sleep changeswere REM sleep specific, as no changes in wake and NREM
sleep was seen in these knockout mice at the baseline and
during sleep rebound. Overall, these results indicate that
Mbnl2 knockout mice exhibit increased REM sleep propensity
and provide a valuable model to study the molecular basis of
REM-associated sleep abnormalities in myotonic dystrophy.
To address additional DM-linked phenotypes in Mbnl2
knockouts, we first mapped the spatial expression pattern of
Mbnl2 in the brain using Mbnl2GT4 heterozygous mice and
tagged allele-specific b-galactosidase expression. This analysis
revealed Mbnl2 expression throughout the brain in both neu-
rons and glia with prominent expression in neurons of the
hippocampus, dentate gyrus, and cerebellar Purkinje cells
(Figures 3A and S2E). Mbnl2 localized predominantly to the
nucleus in these neuronal populations, although in other regions
of the brain, including the cerebral cortex, it was detectable
in both the nucleus and cytoplasm (Figures 3B and S2F).
Mbnl1 is primarily cytoplasmic in some neuronal populations,
such as Purkinje cells (Daughters et al., 2009), but was detect-
able in hippocampal nuclei at a much lower level than Mbnl2Neuron 75, 437–450, August 9, 2012 ª2012 Elsevier Inc. 439
Figure 2. Altered REM Sleep Regulation in Mbnl2 Knockouts
(A) Baseline wake (top), NREM (middle), and REM (bottom) sleep amount changes inMbnl2 wild-type (WT, blue) and knockout (KO, red) mice across 24 hr (n = 8
each for Mbnl2 WT and KO mice; error bars represent SEM). The dark period is indicated by a black bar.
(B) Numbers of episodes (left) and mean episode duration (right four bars) of wake (top), NREM (middle), and REM (bottom) sleep.
(C) REM sleep latency for all REM sleep episodes in Mbnl2 WT and KO during the dark period. The mean REM sleep latency in KO mice (115.8 ± 5.4 s [SEM],
n = 229) was significantly shorter than that of WT (132.3 ± 8.7 s, n = 106), with p = 0.0287 by Mann-Whitney U test.
(D) Time course of NREM (top) and REM (bottom) sleep as percentage of time spent every hour during and after sleep deprivation for 24 hr (one-tailed [*p < 0.05]
and two-tailed [**p < 0.05] Student’s t test).
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hippocampus, a key region of the brain involved in learning
and memory, we next examined whether Mbnl2 loss resulted
in memory impairment as observed in DM patients. To test for440 Neuron 75, 437–450, August 9, 2012 ª2012 Elsevier Inc.spatial memory deficits, we evaluated adult Mbnl2 knockout
and wild-type mice by the Morris water maze test, in which the
mice are trained to locate a submerged platform using visual
cues. Over the training period, both knockout and wild-type
Figure 3. Learning and Memory Deficits, Abnormal Hippocampal Function, and Seizure Susceptibility
(A)Mbnl2 expression in the hippocampus and dentate gyrus. Sections were obtained from wild-type (left) andMbnl2GT4 (right) brains, which carry a gene trap in
Mbnl2 intron 4 that expresses b-galactosidase (b-geo), and stained for b-gal activity (blue) and counterstained with eosin (pink).
(B) Immunohistochemistry of hippocampal sections from Mbnl2+/+ and Mbnl2DE2/DE2 mice using anti-Mbnl2 antibody. Nuclear DNA is indicated by DAPI (blue);
scale bars represent 25 mm.
(C) Spatial memory deficit by the Morris water maze test.Mbnl2+/+ (WT) andMbnl2DE2/DE2 (KO) mice were evaluated for the number of times the missing platform
area was crossed (average crossover). Data are SEM (n = 10 for both experimental groups) and significant (p < 0.05).
(D) NMDA receptor-mediated synaptic potentials are reduced in CA1 of the hippocampus in Mbnl2 knockouts. Representative traces of the NMDAR synaptic
responses and fiber potential (arrowhead) obtained from Mbnl2+/+ (WT, blue) and Mbnl2DE2/DE2 (KO, red) male mice.
(E) Input-output curves for the mean NMDAR EPSP amplitude versus stimulus intensity. Mbnl2 male knockouts (red circles, n = 5/15 mice/slices) exhibited
reduced NMDAR-mediated responses when compared to wild-type (blue circles, n = 3/10 mice/slices). Asterisks indicate significant difference (*p < 0.05).
(F) Mean presynaptic fiber volley amplitude versus stimulus intensity for Mbnl2 wild-type (blue circles, n = 3/15 mice/slices) and knockout (red circles, n = 5/15
mice/slices) male mice.
(G) Time course changes in the field EPSP (left) obtained from hippocampal slices 10min before, and 60 min after, stimulation to induce LTP forMbnl2male wild-
type (blue circles, n = 3/7 mice/slices) and knockouts (red circles, n = 5/10 mice/slices). The bar diagram (right) shows the average magnitude of LTP during the
last 5 min of recording (dotted area in time course) fromMbnl2 wild-type (blue) and knockouts (red). The * indicates a significant difference from baseline (100%)
and # indicates difference between Mbnl2 WT and KO.
(H)Mbnl2 heterozygous (+/, green) and homozygous (/, red) knockout, as well as DMSXL polyCTG transgenic (mu, purple), mice are susceptible to seizures
compared to wild-type sibs (Mbnl2+/+, blue; DMSXLWT, brown) using the following modified Racine scale: 0, no motor seizures; 1, freezing, staring, mouth, or
facial movements; 2, head nodding or isolated twitches and rigid posture; 3, tail extension, unilateral-bilateral forelimb clonus; 4, rearing, immobile state on rear
haunches with one or both forelimbs extended; 5, clonic seizures with loss of posture, jumping, or falling; 6, tonic seizures with hindlimb extension and death.
Indicated data are for males (Mbnl2 n = 4 for WT and KO, n = 6 het; DMSXL n = 10 each for WT and mut) and are significant (*p = 0.05, ***p < 0.001).
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Developmental Control of RNA Splicing in the Brainmice learned to locate the hidden platform but upon platform
removal, Mbnl2 knockouts crossed over the location of the
platform significantly fewer times than wild-type mice, indicating
a deficit in spatial reference memory (Figure 3C).
Since Mbnl2 knockouts exhibited impaired spatial memory
on a hippocampal-dependent task, we performed electrophysi-
ological recordings on hippocampal slices to evaluate the
effects of Mbnl2 loss on NMDA receptor (NMDAR)-mediated
synaptic transmission and synaptic plasticity (long-term poten-
tiation [LTP]). Input-output curves of the NMDAR-mediated
component of the field excitatory postsynaptic potentials
(EPSPs) indicated significant effects of stimulation intensity
[F (7, 161) = 91.77, p < 0.0001] exhibiting a decreased response
in Mbnl2 knockouts when compared to wild-type controls
[F (1, 161) = 21.94, p < 0.0001] (Figures 3D and 3E). The decrease
in the NMDAR component of synaptic transmission was not
due to a loss of synaptic input since the presynaptic fiber volley
amplitudewas similar across the two groups (Figure 3F). Further-
more, the input-output curves of the slope of the synaptic
responses were not significantly different between Mbnl2
wild-type and knockout mice (data not shown), indicating
that the differencewas specific for NMDAR function. For analysis
of synaptic plasticity, LTP-inducing stimulation was delivered to
the test pathway. Although pattern stimulation induced LTP in
wild-type mice compared to the nontetanized path [F (1, 11) =
16.63, p < 0.001], this LTP induction was not observed in five
out of six Mbnl2 knockout mice (wild-type, 134.6 ± 8.09; Mbnl2
knockout, 104.9 ± 5.96) (Figure 3G). Thus, loss ofMbnl2 expres-
sion results in decreased synaptic NMDAR activity, impaired
LTP, and learning and memory deficits.
Another neurologic phenotype, which emerged with low pene-
trance (<10%) in Mbnl2 homozygous knockout males prior to
weaning, was extreme hyperactivity followed by tonic-clonic
seizures and death within 24 hr. To determine whether Mbnl2
deficiency promoted seizure activity, we compared Mbnl2
wild-type with heterozygous and homozygous male knockouts
for seizure susceptibility using the GABA antagonist pentylene-
tetrazole (PTZ). After intraperitoneal injection of PTZ, mice
were evaluated for seizure activity using a modified Racine scale
and by measuring the time to the initial appearance of abnormal
behavior (latency time). Remarkably, a low PTZ dose (40 mg/kg)
was sufficient to generate enhanced seizure incidence, including
tonic-clonic and clonic seizures, even in Mbnl2 heterozygous
knockout mice (Figure 3H). Mbnl2 homozygous knockouts
were more seizure prone and generally died <5min postinjection
after a generalized tonic-clonic seizure or were in a postictal
state for >30 min, while wild-type mice showed reduced activity
after PTZ injection and then behaved normally and rarely devel-
oped seizures. The same Racine score of 6 was obtained for
Mbnl2 knockout females, although the mean latency time
doubled (to100 s). The reason for increased latency in females
is unclear but sex-specific differences in brain function have
been reported previously (Cosgrove et al., 2007).
Because epilepsy is not a common feature of DM, we exam-
ined the seizure-inducing effects of PTZ on DMSXL male
mice, which express a human DMPK transgene carrying a
CTG1200-1700 expansion (Gomes-Pereira et al., 2007). Impor-
tantly, enhanced seizure incidence was also observed in this442 Neuron 75, 437–450, August 9, 2012 ª2012 Elsevier Inc.DM1 mouse model (Figure 3H). Thus, either loss of Mbnl2
or expression of CUGexp RNAs in mice resulted in enhanced
seizure susceptibility. Since Mbnl2 appeared to play a minor
role in developmental splicing regulation in muscle, while
Mbnl2 knockout mice were affected by several neurologic
abnormalities, we next tested whether Mbnl2 functions as an
alternative splicing factor in the brain.
Widespread Alternative Splicing Changes
in theMbnl2 Knockout Brain
Because of high Mbnl2 expression and electrophysiological
deficits in the hippocampus (Figures 1C and 3D–3G), RNAs
were extracted from hippocampi of Mbnl2 wild-type and
knockout adults and analyzed for splicing changes using both
splicing-sensitive microarrays (Du et al., 2010) and RNA-seq
(Wang et al., 2008). For microarrays, alternative cassette
splicing was assessed by separation score (sepscore) analysis,
which measures the difference in the log2 ratio of exon skipping
to inclusion in a mutant versus wild-type transcript (Table S1).
RT-PCR validation rates are typically 85% for splicing
changes with sepscore R 0.3 and q value % 0.05 (Du et al.,
2010; Ni et al., 2007; Sugnet et al., 2006). Using those parame-
ters, we identified 388 cassette exons whose splicing was
significantly altered and an additional 423 splicing changes in
other splicing modes (e.g., retained introns, alternative 30 splice
site [30ss]). One of the misregulated cassettes was in Ndrg4,
a gene in the N-myc downregulated gene family whose expres-
sion is restricted to heart and neurons in the brain and, similar
to Mbnl2 knockouts, Ndrg4/ mice exhibit spatial memory
deficits (Yamamoto et al., 2011). Microarray analysis identified
a 39 nt Ndrg4 exon with enhanced skipping in Mbnl2 knockout
mice (Figure 4A). Splicing-sensitive microarray analysis can
predict binding motifs for splicing factors and earlier studies
discovered that the preferred binding motif for Mbnl1 is
YGCY (where Y is a pyrimidine) (Du et al., 2010; Goers et al.,
2010). Using the top 42 exons, which show enhanced
skipping (sepscore % 0.6) and 47 with elevated inclusion
(sepscore R 0.6), we found prominent enrichment of the same
motif upstream of exons whose inclusion increases in Mbnl2
knockout brain, compared with exons not significantly changed
in the same data set (Figure 4B).
As an alternative approach, we also examined alternative
splicing using paired-end RNA-seq of Mbnl2 wild-type and
knockout hippocampi (Figure 4C; Table S2). In total, we obtained
121million 40 nt paired-end reads from three wild-type and three
knockout animals, respectively, which were mapped to the
mouse reference genome (mm9) or exon junctions (Table S2).
We focused on a comprehensive database of 13,000 cassette
exons annotated based on mRNA/expressed sequence tag
(EST) data and identified 531 cassette exons with Mbnl2-depen-
dent splicing (FDR % 0.15, Fisher’s exact test followed by
Benjamini correction). Among them, we defined a subset of
209 exons with FDR% 0.05 and DIR 0.1 as a high-confidence
set (Table S2). As with splicingmicroarrays, one of the top candi-
dates was Ndrg4 (Figure 4C).
The exons monitored on microarrays and those analyzed
by RNA-seq were compared to evaluate the reliability of
each approach. Among the 3,959 exons on the microarrays,
Figure 4. Mbnl2 Regulates Alternative
Splicing in the Brain
(A) Sepscore analysis of splicing microarray results
for Ndrg4 (39 nt alternative exon 14) in Mbnl2+/+
versus Mbnl2DE2/DE2 mice. The negative sepscore
(1.584) for Ndrg4 exon 14 (39 NT) predicts
enhanced skipping in the Mbnl2 knockout.
(B) Bioinformatics analysis of splicing microarrays
predicts that Mbnl2 recognizes the same binding
motif asMbnl1. Mapping of YGCYmotifs upstream
(left) and downstream (right) of exons that are
preferentially skipped (n = 42, red squares) or
included (n = 47, blue triangles) in Mbnl2 knock-
outs. The frequency of YGCY in 50 nucleotide
windows shifted by 5 nucleotides is compared
to a background set of 2,905 exons whose inclu-
sion does not change in the Mbnl2 knockout.
Error bars mark the 95% confidence interval
around the mean frequency.
(C) Wiggle tracks of tag coverage obtained from
RNA-seq of theNdrg4 locus flanking exon 14 show
enhanced skipping (three biological replicates
each) in Mbnl2DE2/DE2 (bottom, blue cassette) versus Mbnl2+/+ (top, red cassette) mice. Putative Mbnl2 YGCY binding sites located downstream of the Ndrg4
exon 14 50ss are also indicated (turquoise).
(D) Comparison of Mbnl2-dependent exons monitored by microarrays and RNA-seq. Among the 3,222 cassette exons analyzed by both platforms, 116 and 123
exons have high-confidence Mbnl2-dependent splicing, as determined by RNA-seq and splicing microarrays, respectively. Among these, 42 exons were
included in the high-confidence set by both platforms (p < 1.4 3 1032, Fisher’s exact test).
Neuron
Developmental Control of RNA Splicing in the Brain3,222 (81.4%) were also analyzed by our RNA-seq pipeline. In
particular, among the 139 high-confidence Mbnl2-dependent
exons defined by microarray analysis (sepscore R 0.5 and q
value % 0.05), 123 (88.5%) were also analyzed by RNA-seq.
Conversely, 116 of the 209 (55.5%) high-confidence exons
identified from RNA-seq analysis were also analyzed by micro-
arrays. Of the 3,222 exons analyzed by both platforms, 42 exons
were identified as high-confidence exons by both platforms
(Figure 4D). The overlap is highly significant (p < 1.4 3 1032),
albeit imperfect, due to inherent platform differences and the
relatively limited statistical power of each analysis. Nevertheless,
these analyses allowed us to define a combined set of 306
(139 + 209  42) Mbnl2-dependent cassette exons derived
from 271 genes with high confidence in at least one of the
platforms (Table S2). Finally, gene ontology analysis high-
lighted potential roles for Mbnl2 in neuronal differentiation and
development, axon guidance, as well as synaptic functions
(Table S2).
Mbnl2 Regulates Alternative Splicing during Postnatal
Brain Development
We next determined whether these Mbnl2 RNA targets were
developmentally regulated. A number of high-scoring splicing
targets, as well as previously documented DM1 targets Grin1/
Nmdar1 and Mapt, were examined for splicing of relevant
exons in the hippocampus of Mbnl1 and Mbnl2 wild-type and
knockout sibs by RT-PCR (Figures 5A and S3A). Compared to
wild-type sibs, all of these Mbnl2 target exons showed sig-
nificant changes in alternative splicing in Mbnl2 knockouts. In
contrast, the Mbnl2 target exons, except Ryr2, failed to show
significant missplicing in Mbnl1 knockout brain, confirming the
reliability of the Mbnl2 targets identified through genome-wide
analysis and a nonredundant role of Mbnl2 in CNS splicing regu-lation. These splicing patterns were then compared to those
of the forebrain and hindbrain of P6 neonate and P42 adult
WT mice (Figure 5B). Remarkably, the splicing of all the Mbnl2
targets that were examined shifted between P6 and P42 and
Mbnl2 knockout adults retained the fetal-like splicing pattern.
Furthermore, loss of Mbnl2 misregulated these exons by
enhancement of fetal exon inclusion (e.g., Tanc2, Ppp1r12a,
Add1) or adult exon skipping (e.g., Kcnma1, Csnk1d, Cacna1d).
Some of these developmental splicing defects were regional
(Figures 5B and S3B). For example, enhanced skipping of
Ndrg4 exon 14 was observed throughout the P6 brain, while
the fetal pattern for Kcnma1 exon 25a was enhanced skipping
in the forebrain but an increase in inclusion in the hindbrain
(Figure 5B). These results demonstrate that Mbnl2 regulates
a distinct set of exons to promote adult splicing patterns during
postnatal brain development and this regulation varies in
different regions of the brain.
Since both Mbnl2 heterozygous and homozygous knockouts
developed seizures upon PTZ induction, we selected genes
and gene families from the splicing microarray or RNA-seq
data sets (Tables S1 and S2) that had been previously linked
to epilepsy (Klassen et al., 2011) to determine whether any of
these pre-mRNAs showed splicing dysregulation in heterozy-
gous knockouts. Of eight genes assayed (Mbnl2 targets Tanc2
and Csnk1d were included as controls), two (Cacna1d, Ryr2)
showed a significant switch to the fetal pattern in adult
Mbnl2+/DE2 hippocampus. The Cacna1d (CaV1.3) voltage-gated
L-type calcium channel subunit was the most profoundly
affected (Figures 5C and S3C). Missplicing of these pre-mRNAs
in Mbnl2 knockouts was particularly interesting since CUGexp
RNAs have the greatest impact on the expression of genes
involved in calcium signaling and homeostasis (Osborne et al.,
2009).Neuron 75, 437–450, August 9, 2012 ª2012 Elsevier Inc. 443
Figure 5. Regulation of Adult Brain Splicing by Mbnl2
(A) RT-PCR validation of Mbnl2 target exons identified by microarrays and RNA-seq using hippocampal RNAs. Quantification of alternative exon inclusion
(percent spliced in) is shown for ten genes andMbnl1+/+ (blue),Mbnl1DE3/DE3 (purple),Mbnl2+/+ (yellow), andMbnl2DE2/DE2 (turquoise). Data are SEM (n = 3) and
only the differences between Mbnl2+/+ and Mbnl2DE2/DE2 were significant (*p < 0.05).
(B) Loss of Mbnl2 leads to fetal exon splicing patterns. RT-PCR splicing analysis of select Mbnl2 target RNAs inMbnl1+/+,Mbnl1DE3/DE3 (Mbnl1/),Mbnl2+/+, and
Mbnl2DE2/DE2 (Mbnl2/) were compared to the splicing patterns of wild-type P6 and P42 forebrain (fb) and hindbrain (hb). For some exons (Tanc2 E23a), loss of
Mbnl2 completely reproduces the fetal pattern, while for others (Ndrg4, Kcnma1), a partial shift is observed.
(C) Splicing screen of epilepsy-associated genes in wild-type (Mbnl2+/+), Mbnl2+/DE2, and Mbnl2DE2/DE2 reveals dysregulation of Cacna1d exon 12a in hetero-
zygous knockout hippocampus.
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We next used HITS-CLIP to detect target RNAs containing direct
binding sites for Mbnl2 in vivo. After immunopurification of
crosslinked RNA-protein complexes from mouse hippocampi,
extensive RNase A digestion resulted in the appearance of
a major band at 42 kDa in wild-type that was absent in Mbnl2
knockouts (Figure 6A). At a lower RNase concentration, this
distinct band was replaced with a more heterogeneous mixture
of RNA-Mbnl2 complexes from which RNA was isolated and
subsequently sequenced (Licatalosi et al., 2008).
Three CLIP libraries were prepared from independent biolog-
ical replicates. After quality filtering, genomic mapping, and
removal of potential PCR duplicates, we obtained a stringent
set of 703,431 unique CLIP tags that represent independent444 Neuron 75, 437–450, August 9, 2012 ª2012 Elsevier Inc.protein-RNA interactions for further analysis (Table S2). Approx-
imately half (51%) of the unique Mbnl2 CLIP tags were located
on annotated 30 UTRs, making Mbnl2 distinct from other splicing
factors such as Nova and PTB, which primarily bind within
introns (Figure 6B) (Licatalosi et al., 2008; Llorian et al., 2010;
Xue et al., 2009). In addition, there was a substantial number
of intron targets (23%), consistent with a role for Mbnl2 in
splicing. To identify sites of robust Mbnl2-RNA interaction, we
clustered overlapping CLIP tags and conservatively determined
10,408 peaks, whose peak height is significantly above gene-
specific background expected from uniform random distribution
(p < 0.01, Bonferroni correction; Table S2). These peaks were
from 4,792 protein-coding genes, suggesting widespread
Mbnl2-RNA interactions.
Figure 6. HITS-CLIP and the Normalized Mbnl2 RNA Splicing Map
(A) Protein gel autoradiograph of Mbnl2-RNA 32 P-labeled complexes after crosslinking, RNase A digestion (high and low concentrations indicated by slanted
black bar), and immunopurification with anti-Mbnl2.
(B) Pie chart of unique CLIP RNA tag distribution.
(C) Crosslinking-induced mutation site (CIMS) analysis of Mbnl2 CLIP data. The base composition of sequences around CIMS for Mbnl2 (top) and Nova (bottom)
is shown.
(D) De novo motif search using sequences around CIMS (from 10 to +10 nt) and MEME (Bailey and Elkan, 1994).
(E) The majority of alternatively spliced genes in Mbnl2DE2/DE2 knockouts are direct binding targets for Mbnl2.
(F) Normalized complexity Mbnl2 RNA splicing map. Mbnl2 activated (n = 147, red) and repressed (n = 143, blue) exons are shown.
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Figure 7. MBNL2 Brain RNA Splicing
Targets Are Dysregulated in DM1
(A–D) Analysis of DM1 brain for splicing pertur-
bations predicted from the Mbnl2 mouse
knockout model. RT-PCR splicing analysis of
TANC2 (A), KCNMA1 (B), CSNK1D (C), and
CACNA1D (D) using RNAs isolated from normal
control temporal cortex (control, n = 4), disease
control temporal cortex (disease, n = 9), DM1
temporal cortex (DM1, n = 12), fetal control whole
brain (fetal, n = 1), disease control cerebellum
(disease, n = 4), and DM1 cerebellum (DM1, n = 5)
by RT-PCR is shown.
(E) MBNL loss-of-function model for myotonic
dystrophy. MBNL1 and MBNL2 function as
alternative splicing factors during postnatal
development of muscle (red myofibers with blue
myonuclei) and brain (green neuron), respectively.
Note that MBNL1 and MBNL2 cross-regulate the
alternative splicing of key MBNL exons, including
a 54 nt exon (MBNL1 exon 7, MBNL2 exon 6),
which includes a nuclear localization sequence
(Figure S7), so loss of MBNL2 could lead to an
increase in nuclear levels MBNL1 and partial
restoration of adult splicing patterns since both
proteins recognize a YGCY motif.
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refine the Mbnl2 binding motif, we next performed crosslink-
induced mutation site (CIMS) analysis to identify protein-RNA
crosslink sites (Figure 6C and Table S2) (Zhang and Darnell,
2011). De novo motif analysis using 21 nt sequences around
CIMS (10 to +10 nt) highlighted YGCY (UGCU in particular)
as a core element in all top motifs (Figure 6D). The UGCU
elements showed a 16-fold enrichment at CIMS compared to
flanking sequences (Figure S4A) and UGCU was the most en-
riched tetramer (Figure S4B). Deletions, specifically at YGCY
elements, were found in sequences in or near Mbnl2 target
cassette exons (Figure S5). Overall, these data demonstrate
that Mbnl2, like Mbnl1, binds to YGCY elements in vivo to regu-
late splicing.
We next related direct Mbnl2 binding to Mbnl2-dependent
splicing and refined the RNA-map of splicing regulation de-
pending on positions of Mbnl2 binding sites. Analysis of the446 Neuron 75, 437–450, August 9, 2012 ª2012 Elsevier Inc.sequenced CLIP tags confirmed that
the majority (67%–75%) of the targets
identified by both microarrays and RNA-
seq (FDR < 0.05) were direct binding
targets of Mbnl2 in vivo (Figure 6E).
Finally, we examined the distribution of
CLIP tags in 290 (123 + 209  42) high-
confidence Mbnl2 target cassette exons
defined from analysis of microarray or
RNA-seq data and also annotated in our
alternative splicing database. This set
consisted of 147 Mbnl2-activated, and
143 Mbnl2-repressed, cassette exons.
An RNA splicing map derived from this
set of exons revealed that Mbnl2 bind-ing upstream, within, or near the alternative exon 30ss prefer-
entially inhibited exon inclusion, while Mbnl2 binding in the
downstream intron, or near the alternative exon 50ss, generally
favored exon inclusion (Figure 6F). Binding of Mbnl2 60–70 nt
downstream from the 50ss of alternative exons tended to
promote exon inclusion, whereas binding sites overlapping or
immediately downstream of the 50ss repressed exon inclusion.
Mbnl2 Knockouts Model Splicing Shifts in the Human
DM1 Brain
To ascertain whether the target exons identified in Mbnl2
knockouts were similarly misregulated in the DM1 brain, we
tested autopsied human temporal cortex and cerebellar tissues
for missplicing of exons identified as mouse Mbnl2 targets. Of
the 12 target exons examined, 10 were significantly misspliced
in DM1 adult brain to a fetal pattern compared to normal and
other disease controls (Figures 7A–7D and S6A). While there
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that were the most significantly different between normal and
DM1, including CACNA1D, were similarly altered in Mbnl2
knockouts. By contrast, similar splicing trends were not found
in the human cerebellum, perhaps reflecting the shorter CTG
expansion lengths observed in this brain region (Table S5 and
Figure S6B) (Lo´pez Castel et al., 2011). Together, these results
argue that Mbnl2 knockout mice provide a useful model for
altered splicing in the DM brain.
DISCUSSION
RNA-mediated pathogenesis is emerging as an important
disease mechanism in unstable microsatellite disorders (Poulos
et al., 2011). The most recent example is a potential role for
rGGGGCC repeats in autosomal dominant frontotemporal
dementia/amyotrophic lateral sclerosis (FTD/ALS) (DeJesus-
Hernandez et al., 2011; Renton et al., 2011). While the toxic
RNA model for DM is supported by considerable experimental
evidence, recent studies have suggested that other factors
might contribute to disease phenotypes (Sicot et al., 2011; Zu
et al., 2011). Thus, it is important to discriminate between
the relative effects of toxic RNAs and proteins in unstable micro-
satellite diseases. The MBNL loss-of-function model for DM
allows this distinction because specific disease manifestations,
such as myotonia, are replicated in mouse models in the
absence of microsatellite expansions (Poulos et al., 2011).
Mbnl2 Controls Splicing of Numerous Alternative Exons
during Brain Development
Myotonic dystrophy is classified as a muscular dystrophy but
the development and maintenance of normal brain function is
also profoundly affected in this disease. Although DM symptoms
are proposed to result from dysregulation of alternative splic-
ing, the extent of missplicing induced by C(C)UGexp RNAs has
been unclear particularly since previous studies have reported
only a few missplicing events in the DM1 CNS (Jiang et al.,
2004; Sergeant et al., 2001). Here, we tested the hypothesis
that MBNL2 is an important splicing regulator during brain
development and this function is compromised in DM. We
generatedMbnl2 knockout mice and discovered that in contrast
to Mbnl1, Mbnl2 is not an essential alternative splicing factor
during skeletal muscle development. However, Mbnl2 may
play a compensatory role when Mbnl1 expression is compro-
mised. The discordance between our results on the effect of
Mbnl2 loss on skeletal muscle and a previous report using
Mbnl2 gene traps may be attributable to differences in knockout
strategy and the fact that prior studies did not evaluate alter-
native splicing in the CNS (Hao et al., 2008; Lin et al., 2006).
While Mbnl2 knockout mice did not display pronounced
muscle pathology, loss of Mbnl2 resulted in widespread splicing
abnormalities in the brain. During this study, we uncovered a
remarkable similarity between the control of alternative splicing
during postnatal development by Mbnl1 in skeletal muscle and
Mbnl2 in the brain. Both factors promote adult isoform ex-
pression and, similar to Mbnl1, Mbnl2 regulates the develop-
mental splicing of hundreds of alternative cassette exons
via the recognition of a YGCY motif in a manner reminiscent ofthe Nova, Rbfox, and PTBP splicing factor families, although
the binding motifs for these factors are quite different (Du
et al., 2010; Li et al., 2007; Licatalosi and Darnell, 2010; Licatalosi
et al., 2008; Witten and Ule, 2011; Zhang et al., 2008). Thus,
Mbnl2 joins a growing list of alternative splicing factors that
control specific pathways in the brain during development
and/or during adult life. In addition to splicing, our HITS-CLIP
analysis revealed that about half of Mbnl2 targets are located
in annotated 30 UTRs. Since microarray and RNA-seq analyses
did not detect major changes in transcript levels, Mbnl2 may
play important roles in RNA localization and/or translation and
these pathways could also be affected in the DM brain.
Mbnl2 Knockouts: Model for CNS Disease in Myotonic
Dystrophy
Mbnl2 knockout mice show several phenotypes consistent with
abnormalities observed in myotonic dystrophy. For example,
EDS is a common and disabling feature of DM1 (Ciafaloni
et al., 2008; Pincherle et al., 2012; Yu et al., 2011). However,
the molecular basis of this sleep disturbance is unknown. In
some cases with advanced disease, EDS may result from
obstructive sleep apnea (Pincherle et al., 2012). DM1 may also
have direct effects on sleep regulatory circuits in the CNS and
REM sleep changes in patients, including an increase in daytime
and nighttime REM sleep propensity and higher frequency of
sleep onset REM period(s) and REMdensity, have been reported
(Bennett et al., 2007; Ciafaloni et al., 2008; Pincherle et al., 2012).
Here, we demonstrate related REM sleep changes in Mbnl2
knockout mice, including increased REM sleep amounts and
episode numbers. These changes were observed over 24 hr
but were more profound during the active, or dark, period.
Mbnl2 knockouts had twice as many REM sleep episodes com-
pared to wild-type mice, and a large portion of these episodes
had short latencies from the proceeding wake episodes.
Profound REM sleep rebound was also seen inMbnl2 knockout
mice after sleep deprivation and, in contrast, there were no
apparent changes in wake and NREM sleep parameters in
these mutants. Our results indicate that Mbnl2 knockout mice
will be useful to study DM1-associated splicing alternations
that impact sleep regulatory mechanisms.
Additional phenotypes characteristic of DM include mental
retardation in congenital DM1, while childhood through adult
onset disease is associated with learning disabilities, autistic
behavior, impaired cognitive function, cerebral structural
changes, and nonverbal episodic memory impairment (Meola
and Sansone, 2007; Weber et al., 2010). Interestingly, Mbnl2
knockout mice exhibit impaired learning on a hippocampal-
dependent task, a decrease in NMDAR-mediated synaptic
transmission, and an impairment of hippocampal synaptic
plasticity. Several of the misregulated splicing events identified
during this study might contribute to these impairments,
including Cacna1d (McKinney et al., 2009), Tanc2 (Han et al.,
2010), Ndrg4 (Yamamoto et al., 2011), and Grin1 (Shimizu
et al., 2000). For example, DM1 patients exhibit increased
expression of a splice variant of GRIN1 that includes exon 5
(Jiang et al., 2004), which is thought to contribute to the age-
related decline in frontotemporal functions, including memory
(Modoni et al., 2008; Romeo et al., 2010; Weber et al., 2010).Neuron 75, 437–450, August 9, 2012 ª2012 Elsevier Inc. 447
Neuron
Developmental Control of RNA Splicing in the BrainRemoval of exon 5 targets GRIN1 to dendrites (Pal et al., 2003),
suggesting that exon 5 inclusion results in decreased dendritic
localization. Moreover, Tanc proteins interact with PSD-95,
a protein involved in localizing NMDARs at the synapse (Han
et al., 2010). Thus, a decrease in dendritic GRIN1 or altered
regulation of NMDARs could underlie the decrease in the
synaptic NMDAR response, impaired LTP, and learning and
memory deficits.
While there have been sporadic reports of epilepsy associated
with DM, this is not a characteristic overt feature of this disease
(Meola and Sansone, 2007). However, DM patients show
enhanced sensitivity to barbituates and benzodiazepines, which
enhance the activity of the GABAA receptor (Harper, 2001).
Moreover, the relevance of this hyperexcitability phenotype to
DM1 is also supported by our observation that seizures were
induced with a GABA antagonist in both Mbnl2 knockouts and
the DMSXL transgenic model for DM1. Because the expression
of a large CTG expansion in the DMSXL brain is sufficient to
increase seizure susceptibility in mice, this study provides the
cautionary note that DM may possess some features of an
excitability disorder. Finally, we also noted a difference in the
latency time to the appearance of the seizure phenotype
between males and females, which could reflect sex-specific
differences in the alternative splicing of seizure-associated
genes.
Based on these and additional findings, we propose a
modified MBNL combinatorial loss-of-function model for DM.
MBNL proteins function as alternative splicing factors during
postnatal development, with MBNL2 the predominant factor
in the brain, while MBNL1 serves a similar role in skeletal
muscle (Figure 7E). Thus, we anticipate that major pathological
changes in the DM brain are attributable to toxic RNA ex-
pression, MBNL2 sequestration by C(C)UGexp RNAs, and dys-
regulation of specific alternative splicing events required for
normal adult CNS function.
EXPERIMENTAL PROCEDURES
Mbnl2 Knockout Mice
The Mbnl2 targeting vector was derived from CHORI clone bMQ-63F6. A
10 kb fragment containing Mbnl2 was subcloned into PL253 (protocols
1–4, http://web.ncifcrf.gov/research/brb/protocol.aspx). The targeting con-
struct (Figure S1B, Table S3 for PCR primers) was linearized with NotI and
electroporated in 129 SvlmJ ES cells, followed by selection as described
(Kanadia et al., 2003). For constitutive Mbnl2 knockouts, Mbnl2+/con mice
were mated to B6.C-Tg(CMV-cre)1Cgn/J mice (JAX). All animal procedures
were approved by the University of Florida IACUC. Mouse tissue protein
and RNA analyses (Kanadia et al., 2006), immunohistochemistry and X-Gal
staining (Emamian et al., 2003), and rotarod analysis (Daughters et al.,
2009) were performed as described previously with some modifications
(see Supplemental Experimental Procedures).
Sleep/REM Analysis
Implant surgery, EEG/EMG monitoring, and EEG data acquisition were per-
formed on 6-month-old mice (n = 8 for each genotype) as described (Fujiki
et al., 2009). Wakefulness was determined by low amplitude and mixed
frequency (>4 Hz) EEG was determined with continuous large fluctuation in
EMG, and NREM sleep was determined by high-amplitude and low-frequency
(0.5–4 Hz) EEG with no fluctuation in EMG. REM sleep was determined by
low-amplitude and high-frequency EEG (similar to wake stage, but with
rhythmic theta waves at 7–9 Hz) with low-amplitude EMG. REM theta448 Neuron 75, 437–450, August 9, 2012 ª2012 Elsevier Inc.EEG power was analyzed with fast Fourier transform for band frequencies
between 4–9 Hz. Sleep deprivation was initiated from ZT 0 for 6 hr with gentle
handling.
Morris Water Maze, Electrophysiology, and Seizure Susceptibility
Mice were tested for spatial learning and memory using a Morris water maze
as described with several modifications (Han et al., 2010). Mice were allowed
to swim (1 min) during the training period (4 trials/day for 5 days) and then
allowed to rest on the platform. During the examination day, mice were
randomly placed in the three nontarget quadrants and allowed to swim for
1 min. For electrophysiology, hippocampal slices (400 mm) were processed
and recordings obtained as described (Foster et al., 2008) (see Supplemental
Experimental Procedures). Mice (2–5 months) were also tested for seizure
susceptibility after injection (40 mg/kg) with pentylenetetrazol. After injection,
the mice were placed in an observational area for 60 min and the time of
onset of convulsive behavior and nature and severity of the convulsion were
scored according to a modified Racine scale (Lu¨ttjohann et al., 2009).
Splicing Microarrays, Paired-End RNA Sequencing, and HITS-CLIP
For splicing microarrays and RNA-seq, hippocampal RNAs were obtained
from Mbnl2+/+ and Mbnl2DE2/DE2 mice (2–3 months, n = 3 each). Splicing
microarray analysis was performed as described (Du et al., 2010) with
modifications (see Supplemental Experimental Procedures). For RNA-seq,
RNAs were purified and sequencing libraries were constructed using the
mRNA-Seq 8-Sample Prep Kit according to the manufacturer’s protocol
(Illumina). Libraries were sequenced (40 cycles, both ends) using an Illumina
Genome Analyzer IIx. Raw sequence reads were mapped back to the mouse
reference genome together with a database of annotated exon junctions
compiled from mouse, human, and rat mRNA/EST data. CLIP was performed
as reported (Jensen and Darnell, 2008) with modifications (see Supplemental
Experimental Procedures).
Human RNA and Splicing Analysis
Temporal cortex and cerebellar autopsy tissues (12 DM1 patients, 9 disease
controls) were analyzed (Table S5). This research was approved by the
Institutional Ethics Committee and written informed consent for specimen
research use was obtained from all patients. RNA was extracted using the
ISOGEN procedure (Nippon Gene) and cDNA was synthesized using 1–3 mg
of RNA. Random hexamers and cDNA equivalent to 20 ng RNA was PCR
amplified for initial denaturation at 94C for 10 min and 35 cycles (94C for
30 s, 55C for 30 s, and 72C for 30 s) (Table S6). PCR products were analyzed
by capillary electrophoresis (Hitachi Electronics). The percentage of each
peak was obtained by dividing each signal by the total signal and statistical
analysis was performed using the Mann-Whitney U test.
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Microarray and RNA-seq data have been deposited in GEO under accession
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